Private equity
Equity investment
The founder of GOWIN Semiconductor Corp., is from Lattice. The Company is an FPGA manufacturer with completely independent intellectual property rights. The Company is committed to providing FPGA chips, software, IP, reference designs, development boards and FPGA overall solutions. The Company is also the only FPGA company in China with automotive chip certification.
Equity investment
3peak Incorporated (A-share: 688536) is an integrated circuit design company focusing on the R&D and sales of analog integrated circuit products, which received strategic investment from Huawei in the start-up stage. The Company has always adhered to the research and development of high-performance, high-quality, and high-reliability analog integrated circuit products, and completed its IPO listing on the China Science and Technology Innovation Board in 2020.
This portfolio has been invested through the PRC fund which is managed by the team members.
BA7, as the only venture capital firm outside Japan involved in Jpharma's E3 financing round, participated in this transaction.
J-Pharma Co., Ltd. aims to “pursue new possibilities for SLC transporters and contribute to the health and hope of people worldwide through the development of innovative new drugs that address unmet medical needs.”
J-Pharma Co., Ltd. (Headquarters: Yokohama, Kanagawa, Japan; President & CEO: Masuhiro Yoshitake) has completed a total of 3.77 billion yen raised from Japan and foreign investors in the E-round extension, which had been ongoing since June 2024 (including payments scheduled for April 2025). In addition, the Company has received a grant of up to 2 billion yen from the Japan Agency for Medical Research and Development (AMED) under its “Drug Discovery Venture Ecosystem Enhancement Project”. As a result, the total amount of funds secured since June 2024 has reached up to 5.77 billion yen. Including previous funding rounds and grants, J-Pharma’s cumulative funding now totals a maximum of 13 billion yen.
Background and Purpose of Fund Procurement
The Company raised funds to accelerate the research and development of LAT1 (L-type amino acid transporter 1) inhibitors, nanvuranlat and JPH034. For nanvuranlat, the Phase 2 clinical trial in Japan for patients with refractory biliary tract cancer was successfully completed, and in the second quarter of fiscal year 2024, an agreement was reached with the U.S. FDA on the design of a global Phase 3 clinical trial. We aim to start a global Phase 3 clinical trial of nanvuranlat in fiscal year 2025 and to obtain global approval in fiscal year 2030.
JPH034 is an LAT1 inhibitor being developed for multiple sclerosis, and we plan to file an Investigational New Drug (IND) application with the U.S. FDA and start Phase 1 clinical trial in the U.S. during fiscal year 2025, accelerating development with a view to global expansion. We will continue to strive to be a successful example of a Japanese drug discovery venture and to develop innovative drugs that offer hope to patients around the world.
BA7 stated that, as an important step in implementing its ESG and diversity strategy, J-Pharma will become a significant representation of its presence in the Japanese venture capital market.BA7 is committed to being a solid partner on the company’s growth path, leveraging our extensive experience in the global capital markets to support the company’s future development.